

Company Flash


11 October 2007 | 9 pages

Infosys Technologies (INFY.BO)

Buy: Operationally Strong 2Q

- In-line 2Q FY08 Revenue was US\$1,022m (vs. our estimate of US\$1,017m) and net profit Rs11bn (Rs10.9bn). The EBITDA margin surprised on the upside: a sharp ~250bp expansion was led by pricing increases. But higher tax rate resulted in in-line net profits.
- **FY08 guidance raised** Infosys raised its guidance again. Revenue guidance (US\$ terms) was raised to US\$4.16-4.17bn (+34.6-35% yoy) and EPS guidance was upped marginally to Rs79.5-79.9 (+~19% yoy).
- **Strong pricing** The pricing trend remains positive, up ~2% sequentially (on a blended basis). YoY, onsite pricing is up ~8% and offshore pricing +~7%.
- Volume growth muted again; hiring guidance raised Volume growth in 2Q was 7.7% qoq, lower than our estimate. Hiring was slow in the quarter at ~4,500 employees; management attributed this to delayed infrastructure rampup. Management raised its FY08 hiring guidance to ~30,000 (~1,500 from Philips acquisition) from ~26,500.
- Clarity on 2008 IT budgets the key Key investor concerns continue to be (1) INR appreciation and (2) clarity over 2008 IT budgets. Infosys' management indicated on CNBC that as of now they do not see any slowdown in IT spending. Clarity on IT budgets should emerge only over the next few months. Infosys trades at ~20x FY09E EPS.

Buy/Low Risk	1L
Price (11 Oct 07)	Rs1,978.55
Target price	Rs2,440.00
Expected share price return	23.3%
Expected dividend yield	0.8%
Expected total return	24.1%
Market Cap	Rs1,130,167M
	US\$28,875M



Statistical	Ahetraet
Statistical	MUSLIAGE

Source: Powered by dataCentral

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2006A	24,599	43.82	27.5	45.2	15.6	40.4	1.1
2007A	38,560	67.76	54.6	29.2	9.9	42.3	0.6
2008E	46,004	80.24	18.4	24.7	7.6	35.1	0.8
2009E	56,389	98.35	22.6	20.1	5.8	32.8	1.0
2010E	64,658	112.77	14.7	17.5	4.6	29.4	1.2

Surendra Goyal, CFA¹

+91-22-6631-9870 surendra.goyal@citi.com

Hitesh Shah, CFA¹

+91-22-6631-9872 hitesh.b.shah@citi.com

Vishal Agarwal¹ vishal1.agarwal@citi.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

¹Citigroup Global Markets India Private Limited

Other key details

- Forward cover at the end of the quarter was US\$1.4bn (vs. US\$925m at the end of the previous quarter).
- Infosys has made 18,000 offers to campus engineers for next year.
- BFSI spend indicators do not indicate any slowdown as per Infosys's head of BFSI.
- Infosys BPO had a mixed quarter revenue growth was slow at ~7% qoq at US\$53m but margins improved ~300bp qoq and attrition fell to ~35%.
- Philips BPO deal done in this quarter was the largest deal in the history of Infosys (revenue of ~US\$250m). Infosys also talked about another large (sub US\$100m) deal in the transportation space in Canada.
- Infosys management indicated that 12-14 large deals were in the pipeline, of which ~70% were US\$100m+ in size.

Figure 1. Key Financials (Rs mn)

	2007	1008	2Q08	QoQ	YoY
Revenue (US\$ m)	746	928	1,022	10.1%	37.0%
Revenue	34,510	37,730	41,060	8.8%	19.0%
Cost of revenue	18,330	21,690	22,310	2.9%	21.7%
Gross profit	16,180	16,040	18,750	16.9%	15.9%
Gross margin	46.9%	42.5%	45.7%	315bp	-122bp
Operating expenses	5,090	5,200	5,910	13.7%	16.1%
EBITDA	11,090	10,840	12,840	18.5%	15.8%
EBITDA margin	<i>32.1%</i>	<i>28.7%</i>	31.3%	254bp	-86bp
Depreciation and amortization	1,220	1,440	1,440	0.0%	18.0%
EBIT	9,870	9,400	11,400	21.3%	15.5%
EBIT margin	28.6%	24.9%	27.8%	285bp	-84bp
Other income	660	2,530	1,540	-39.1%	133.3%
Profit before tax	10,530	11,930	12,940	8.5%	22.9%
Income tax expense	1,230	1,140	1,940	70.2%	57.7%
Income from operations	9,300	10,790	11,000	1.9%	18.3%
Affiliates/Minority	-10	0	0	n.a	n.a
Net income - recurring	9,290	10,790	11,000	1.9%	18.4%
EO income/(loss)	0	0	0	n.a.	n.a.
Net profit	9,290	10,790	11,000	1.9%	18.4%
EPS - basic	16.75	18.89	19.26	1.9%	15.0%
EPS - fully diluted	16.36	18.82	19.19	2.0%	17.3%

Source: Company Reports

Figure 2. 3Q FY08 Guidance

Infosys	Guidance		Implied gro	wth
3Q08 guidance	Lower	Upper	Lower	Upper
Revenue (Rs m)	42,380	42,580	3.2%	3.7%
Revenue (\$ m)	1,073	1,078	5.0%	5.5%
EPS - basic (Rs)	20.11	20.11	4.4%	4.4%

Source: Company Reports

Figure 3. FY08 Guidance Revision

Infosys	Guidance		Guidance post 1Q08		Guidance revision Guidance post 2008		Guidance i	evision		
FY08 guidance	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
Revenue (Rs m)	170,380	173,080	162,380	164,330	-4.7%	-5.1%	165,880	166,480	2.2%	1.3%
Revenue (\$ m)	3,950	4,020	4,000	4,050	1.3%	0.7%	4,160	4,170	4.0%	3.0%
EPS - basic (Rs)	80.29	81.58	78.20	79.00	-2.6%	-3.2%	79.49	79.88	1.6%	1.1%
INR/USD assumption		43.10		40.58		-5.8%		39.50		-2.7%

Source: Company Reports

Figure 4. Performance vs. Guidance

Infosys - 2008	Actual	Guida	nce	Outperforma guidan	
		Lower	Upper	Lower	Upper
Revenue (Rs m)	41060	39,520	39,930	3.9%	2.8%
Revenue (\$ m)	1022	974	984	4.9%	3.9%
EPS - basic (Rs)	19.26	18.88	18.88	2.0%	2.0%

Source: Company Reports

Figure 5. Performance vs. Expectation

Infosys - 2Q08	Actual	Expectations Citi	Outperformance Citi
Revenue (Rs m)	41,060	41,095	-0.1%
Revenue (\$ m)	1,022	1,017	0.5%
Net profit(Rs m)	11,000	10,876	1.1%
EPS - basic (Rs)	19.26	19.04	1.1%

Source: Company Reports, Citi Estimates

	1Q07	2Q07	3Q07	4Q07	1Q08	2Q08
IT and BPO professionals	54,606	61,966	65,293	68,156	71,018	75,313
- Billable	48,438	53,873	58,073	61,917	63,895	66,743
- Banking Business Unit	1,817	1,809	1,967	2,053	2,053	2,053
- Trainees	4,351	6,284	5,253	4,186	5,070	6,517
Sales & support	3,803	4,184	4,039	4,085	4,953	5,188
Total employees	58,409	66,150	69,332	72,241	75,971	80,501
Gross addition	8,097	10,795	6,062	5,990	7,004	8,543
Net addition	5,694	7,741	3,282	2,809	3,730	4,530
Attrition % (TTM) - Infosys stand alone	11.9%	12.9%	13.5%	13.7%	13.7%	14.2%
Utilization						
- including trainees	71.1%	67.5%	67.5%	67.9%	70.5%	70.3%
- excluding trainees	76.1%	77.5%	75.8%	73.0%	73.9%	77.8%

Source: Company Reports

F:	7	V	Free sentions	M-4-:
Figure	1.	ĸev	Execution	Metrics

	1Q07	2Q07	3Q07	4Q07	1Q08	2Q08
Infosys consolidated						
Billed effort (person-months)	109,818	121,845	133,711	138,852	148,359	159,203
- Onsite	30,051	33,346	35,368	36,752	39,043	40,936
- Offshore	79,767	88,499	98,343	102,100	109,316	118,267
Billed effort distribution (%)						
- Onsite	27.4%	27.4%	26.5%	26.5%	26.3%	25.7%
- Offshore	72.6%	72.6%	73.5%	73.5%	73.7%	74.3%
Revenue distribution (%)						
- Onsite	50.5%	50.3%	49.2%	49.8%	49.7%	48.8%
- Offshore	49.5%	49.7%	50.8%	50.2%	50.3%	51.2%
IT Services						
Billed effort distribution (person-months)	90,198	100,292	107,679	111,587	119,322	128,457
- Onsite	29,861	33,146	35,175	36,584	38,882	40,740
- Offshore	60,337	67,146	72,504	75,003	80,440	87,717
Billed effort distribution (%)						
- Onsite	33.1%	33.0%	32.7%	32.8%	32.6%	31.7%
- Offshore	66.9%	67.0%	67.3%	67.2%	67.4%	68.3%
Revenue distribution (%)						
- Onsite	54.4%	54.4%	54.0%	54.3%	54.1%	53.2%
- Offshore	45.6%	45.6%	46.0%	45.7%	45.9%	46.8%

Source: Company Reports

Figure 8. Revenue Mix

	1007	2007	3Q07	4Q07	1Q08	2008
Geographic wise						
North America	64.0%	63.7%	63.2%	62.6%	62.6%	62.6%
Europe	26.2%	25.8%	26.8%	26.6%	26.8%	27.4%
India	1.4%	1.6%	1.8%	1.5%	1.8%	1.0%
RoW	8.4%	8.9%	8.2%	9.3%	8.8%	9.0%
Service line wise						
Development	21.3%	21.4%	20.1%	21.3%	19.6%	20.2%
Maintenance	29.9%	29.2%	29.8%	28.4%	29.5%	27.9%
Re-engineering	2.6%	2.3%	2.1%	1.5%	2.0%	1.6%
Package implementation	16.5%	17.0%	17.9%	18.4%	18.4%	18.7%
Consulting	3.0%	3.6%	3.3%	4.3%	4.9%	5.0%
Testing	6.2%	6.8%	7.0%	7.3%	7.5%	7.8%
Engineering services	1.8%	1.6%	1.5%	1.6%	1.4%	1.6%
Business process management	4.2%	4.5%	4.9%	5.2%	5.4%	5.2%
Other services	10.8%	9.9%	9.1%	8.2%	8.1%	8.3%
Products	3.7%	3.7%	4.3%	3.8%	3.2%	3.7%
Vertical wise						
Insurance	7.0%	6.7%	7.6%	7.4%	7.0%	7.7%
Banking & FS	29.4%	30.7%	31.0%	29.6%	29.1%	28.8%
Manufacturing	14.5%	14.0%	12.8%	12.9%	13.6%	13.9%
Retail	9.7%	9.0%	10.5%	10.8%	10.8%	12.5%
Telecom	17.7%	18.9%	18.3%	21.9%	22.0%	20.6%
Energy & Utilities	5.4%	5.6%	5.4%	4.8%	4.9%	5.3%
Transportation & Logistics	3.3%	2.7%	2.0%	1.8%	2.3%	2.3%
Services	8.7%	7.7%	8.3%	7.9%	7.6%	7.7%
Others	4.3%	4.7%	4.1%	2.9%	2.7%	1.2%

Source: Company Reports

Eiguro	۵	Kov	Cliont	Metrics
FIGURE	Э.	rev	Guent	Metrics

	1Q07	2Q07	3Q07	4007	1Q08	2Q08
Active Clients	469	476	488	500	509	520
Added during the quarter	38	45	43	34	35	48
No. of million dollar clients	221	232	256	275	285	295
No. of 5mn+ dollar clients	94	97	108	107	113	122
No. of 10mn+ dollar clients	56	61	67	71	75	77
No. of 20mn+ dollar clients	28	29	35	36	40	44
No. of 30mn+ dollar clients	19	20	22	25	26	30
No. of 30mn+ dollar clients	19	20	22	25	26	30
No. of 40mn+ dollar clients	15	16	17	16	18	22
No. of 70mn+ dollar clients	7	8	10	11	11	11
No. of 90mn+ dollar clients	3	3	4	4	8	9
Clients accounting for > 5% of revenue	1	1	1	1	1	1
Revenue - top client	5.8%	6.6%	6.9%	8.5%	8.6%	7.9%
Revenue - top 5 client	19.5%	21.0%	18.9%	21.3%	21.4%	19.5%
Revenue - top 10 client	31.7%	32.9%	31.0%	33.4%	32.3%	29.9%
Repeat Business	0.97	0.952	0.947	0.933	0.995	0.977
DSO - TTM (in days)	65	65	63	64	62	61

Source: Company Reports

Infosys Technologies

Company description

Infosys is the second-largest IT services company in India with more than 66,000 professionals. It is also among the fastest-growing IT services organization in the world, and is a leader in the offshore services space. Infosys provides business consulting, application development and maintenance and engineering services to more than 475 active clients across verticals such as Banking, Financial Services, Insurance, Retail, Manufacturing, and Utilities in the Americas, Europe and Asia Pacific. Infosys sells a core banking application, Finacle, which is used by leading banks in India, the Middle East, Africa and Europe. Its subsidiary, Infosys BPO (formerly Progeon), which employs more than 11,000 people, is a provider of BPO services. It launched a subsidiary in April 2004, Infosys Consulting, which provides high-end IT consulting services.

Investment strategy

We rate Infosys as Buy/Low Risk (1L). We are positive on the stock from a fundamental 12-month view. Offshore IT outsourcing has now become a mainstream option, and we think scale and scalability, along with an ability to move up the value chain, are key criteria for successful offshore IT vendors. In this respect, Infosys appears well positioned and continues to gain ground given its strong branding and industry-leading sales force. Infosys should see above-industry average volume growth along with modest pricing improvement. We expect Infosys to deliver revenue CAGR of 24.5% and EPS CAGR of 19.1% for FY07-10. Unlike many other high-growth firms in other industries, Infosys continues to generate solid FCF, and its RoE of 40%+ continues to be well above its cost of capital.

Valuation

Our target price of Rs2,440 is based on 25x FY09E EPS. This is close to the midpoint of the last one-year trading band of 20-28x 1-year forward earnings and factors in some deceleration in growth. We are now forecasting 19% earnings growth (on a high base of FY07) with some upside potential from pricing improvement and/or rupee depreciation. This is also supported by comparing it with global peers and the broader Indian market. The 25x multiple was also derived from a P/E band analysis of Infosys' trading pattern. During slowdowns in tech and offshore IT services, Infosys has traded at an average one-year rolling P/E of 25.1x with a low of 13x. Our estimates continue to assume a certain P/E premium to the market; this is justified, in our view, given the strong FCF, ROIC and growth rates for Infosys vs. the overall market. We believe P/E remains the most appropriate valuation measure given Infosys' profitable record and high earnings visibility.

Risks

We rate Infosys shares as Low Risk, which is consistent with our quantitative risk-rating system that tracks historical share price volatility. The key downside risks to the shares reaching our target price include: (1) any significant appreciation of the rupee against the US dollar/euro/pound; (2) pressure on billing rates (as Infosys continues to enjoy a 10-15% premium in its billing rates); (3) a sharp slowdown in the US economy; and (4) limited H1B visa quotas.

Appendix A-1

Analyst Certification

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

IMPORTANT DISCLOSURES



Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Infosys Technologies in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Infosys Technologies.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Infosys Technologies.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

The Firm is a market maker in the publicly traded equity securities of Infosys Technologies.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution			
Data current as of 30 September 2007	Buy	Hold	Sell
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%
% of companies in each rating category that are investment banking clients	53%	55%	42%

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or

more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underper

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 11 October 2007 10:24 AM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by

Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong, Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl., Jend. Sudirman Kay. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor, Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service marks of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.